title: Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
abstract: A specific type of myelodysplastic syndrome (MDS) is associated with isolated deletion on the long arm of chromosome 5, i.e., 5q-syndrome (del(5q)). The treatment approaches for MDS del(5q) include the immunomodulating drug lenalidomide (LEN). Thirteen MDS del(5q) patients were included in this study. We found elevated activities of lactate dehydrogenase (LDH) and matrix metalloproteinase 9 (MMP-9) in the blood plasma of MDS del(5q) patients as compared with healthy controls. This was stabilized to control values after LEN treatment. Similar behavior we registered also for the thioredoxin and calnexin contents in BP. Peripheral blood mononuclear cells (PBMC) from patients with MDS del(5q) prior to and after treatment with LEN did not exhibit any detectable amount of P-glycoprotein (P-gp) gene transcript. However, we detected a measurable amount of multidrug resistance associated protein 1 (MRP1) mRNA in PBMCs from three patients prior to LEN treatment and in one patient during LEN treatment but it was not present prior to treatment. These data indicated on usefulness of applied protein markers estimation for monitoring of MDS del(5q) patient treatment effectiveness by LEN. Expression of MRP1 seems to be independent on LEN treatment and reflects probably the molecular variability in the ethiopathogenesis of MDS del(5q).
authors.forename: Lucia
authors.initials: L
authors.lastname: Messingerová
authors.forename: Anna
authors.initials: A
authors.lastname: Jonášová
authors.forename: Miroslav
authors.initials: M
authors.lastname: Barančik
authors.forename: Lenka
authors.initials: L
authors.lastname: Poleková
authors.forename: Mário
authors.initials: M
authors.lastname: Šereš
authors.forename: Lenka
authors.initials: L
authors.lastname: Gibalová
authors.forename: Albert
authors.initials: A
authors.lastname: Breier
authors.forename: Zdena
authors.initials: Z
authors.lastname: Sulová
mesh_terms: D000328:Adult; D000368:Aged; D000748:Anemia, Macrocytic / Q000097:blood* / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000032:analysis*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D007155:Immunologic Factors; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000097:blood; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000188:drug therapy*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D007155:Immunologic Factors; D000077269:Lenalidomide; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D013792:Thalidomide; C421109:multidrug resistance-associated protein 1